Dezoksinat - instructions for use, dose, side effects, contraindications

Active substanceSodium deoxyribonucleateSodium deoxyribonucleate

Similar drugsTo uncover

Deoxynate®

solution locally externally

FARMZASCHITA NPC, FSUE Russia

Derinat®

solution locally externally

FarmPack, LLC Russia

Derinat®

solution w / m

FarmPack, LLC Russia

Ridostin

solution w / m in / skin

DIAPHARM, LLC Russia

Dosage form: & nbspsolution for local and external use

Composition:Per 1 ml:

Active substance: Deoxynate® (sodium deoxyribonucleate) 2.5 mg.

Excipients: methylparahydroxybenzoate (nipagin) 1.0 mg, sodium chloride 9.0 mg, water for injection up to 1 ml.

Description:

Colorless, clear liquid.

Pharmacotherapeutic group:Immunomodulating agent

ATX: & nbsp

L.03.A.X Other immunostimulants

Pharmacodynamics:

The drug Dezoksinat® activates cellular and humoral immunity. The drug Dezoksinat ® has a curative effect for ulcerative necrotic lesions of the skin and mucous membranes of various locations. The use of the drug Dezoksinat® in the form of dressings, applications and rinses has an analgesic effect, reduces the manifestation of the inflammatory reaction, activates the growth of granulations and epithelium. With suppuration processes at the regeneration stage, the preparation Deoxynate® leads to faster healing. Promotes an increase in engraftment of autografts on burn surfaces, as well as allografts in the plastic of defects in the maxillofacial region.

The use of the drug Dezoksinat ® is not accompanied by toxic and allergic reactions.

Pharmacokinetics:

The drug Dezoksinat ® with local application is rapidly absorbed and distributed in organs and tissues with the participation of the endolymphatic pathway. In the phase of intensive drug delivery to the blood, a redistribution occurs between the plasma and the formed elements of the blood, in parallel with the metabolism and excretion. The drug Dezoksinat® is metabolized in the body. The final metabolites are xanthine, hypoxanthine, beta-alanine, acetic, propionic and uric acids, which are excreted from the gastrointestinal tract. Excreted from the body (in the form of metabolites) by the kidneys by bi-exponential dependence and, in part, through the gastrointestinal tract.

Indications:

Primary, late radiation ulcers and thermal skin burns II-III severity, acute radial pharyngeal syndrome, trophic ulcers, disruption of the integrity of the mucous membrane of the oral cavity, nose, vagina, rectum, decubital ulcers in the oral cavity and on the skin; complications associated with cytotoxic therapy (stomatitis, pharyngo esophagitis, gingivitis, uvulitis, enterocolitis, vulvovaginitis,paraproctitis), in the preparation of tissues for auto- or allotransplantation and during transplant engraftment.

Contraindications:

Individual intolerance to sodium deoxyribonucleate or any other component of the preparation Deoxynate®.

Pregnancy and lactation:

It is not recommended to use the drug in pregnant women and during breastfeeding.

Dosing and Administration:

The drug is prescribed to children from the first day of life and adults.

For the treatment of skin lesions apply application dressings with a solution of the drug Dezoksinat®, replaced 3-4 times a day.

With lesions of the oral mucosa rinsing with a solution of the drug Dezoksinat ® (4 times a day for 5-15 ml with subsequent ingestion).

In the vagina The preparation Dezoksinat® is injected on a tampon, in the rectum - in the enema (20-50 ml).

The duration of the course of treatment is until the signs of inflammation and epithelization of the skin and mucous membranes disappear persistently (4-10 days).

Side effects:

When used topically, Dezoxinate® does not cause side effects.

If any of the side effects listed in the manual are aggravated, or if you notice any other side effects not listed in the instructions, inform the doctor about it.

Overdose:

Not detected.

Interaction:

When topical application is not compatible with ointments on fat basis and solutions of hydrogen peroxide.

Special instructions:

The drug Deoxynate ® is ineffective in extremely severe forms of lesions, extensive deep necrosis, attributable to the IV degree of severity.

Read the instructions carefully before using the product. Keep the manual, it may be needed again. If you have any questions, contact your doctor. The medicine you are treating is intended for you personally, and it should not be passed on to others, as it can harm them even if you have the same symptoms as you.

Effect on the ability to drive transp. cf. and fur:Data on the adverse effect of the drug on the ability to manage vehicles and mechanisms are absent.

Form release / dosage:Solution for topical and topical use, 2.5 mg / ml.

Packaging:

50 ml in bottles for infusion solutions, hermetically sealed with rubber stoppers with aluminum or aluminum-plastic caps.

The bottle together with the instruction for use is placed in a pack of cardboard.

Storage conditions:

In a dry, the dark place at a temperature of 5 to 10 ° C. Keep out of the reach of children.

Shelf life:

3 years.

Do not use after the expiration date printed on the package.

Terms of leave from pharmacies:On prescription

Registration number:LP-000520

Date of registration:01.03.2011 / 09.01.2017

Expiration Date:Unlimited

The owner of the registration certificate:FARMZASCHITA NPC, FSUE FARMZASCHITA NPC, FSUE Russia

Manufacturer: & nbsp

FARMZASCHITA NPC, FSUE Russia

Information update date: & nbsp22.04.2017

Illustrated instructions

Instructions

Deoxynate® (Desoxynatum®)